Abstract: Topical anti-pruritic compositions and methods of using the same to treat pruritus. These anti-pruritic compositions are capable of temporarily or permanently reducing, inhibiting, treating, ameliorating, and/or preventing pruritic skin conditions, as well as other related skin conditions. In a particular aspect, the present formulations provide a quicker and more effective treatment of pruritus than do certain present pruritus-treating compositions.

Abstract: Topical cosmetic compositions are provided that can comprise a Phyllanthus extract, a Bellis extract, and a licorice (Glycyrrhiza) extract. These compositions are used for topical cosmetic applications, particularly to lighten skin. Methods for lightening skin are also provided and can comprise topically administering a therapeutically effective amount of a topical cosmetic composition comprising a Phyllanthus extract, a Bellis extract, and a licorice extract, to skin of a subject in need thereof.

Abstract: Topical cosmetic compositions are provided that can comprise a Phyllanthus extract, a Bellis extract, and a licorice (Glycyrrhiza) extract. These compositions are used for topical cosmetic applications, particularly to lighten skin. Methods for lightening skin are also provided and can comprise topically administering a therapeutically effective amount of a topical cosmetic composition comprising a Phyllanthus extract, a Bellis extract, and a licorice extract, to skin of a subject in need thereof.

Abstract: A topical composition and methods of using same for treating various skin disorders or conditions. In a particular aspect, these compositions comprise a storage-stable benzoyl peroxide-containing composition in suspension and an antibiotic or pharmaceutically acceptable salt or ester thereof in solution and a retinoid or a pharmaceutically acceptable salt thereof in suspension, wherein the topical composition has a final pH of about 3 to about 8. In an alternative embodiment, these compositions comprise a storage-stable mixture of a retinoid or a pharmaceutically acceptable salt thereof and either a benzoyl peroxide-containing composition or clindamycin or a pharmaceutically acceptable salt thereof.

Abstract: The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.

Abstract: The present invention relates to non-aqueous emulsions stabilised by silica particles and to processes for making them. The invention further comprises: a particle stabilized oil-in-polar (o/polar o/p) emulsion comprising: a) a dispersed oil phase, b) a continuous polar phase substantially free of water, c) a particulate solid which is a silica particle dispersant possessing surface silanol groups (SiOH) sufficient to stabilize the emulsion, and where the emulsion is substantially free of emulsifiers, surfactants; and wherein the oil phase (a) is dispersed as discontinuous droplets in the polar phase (b); the silica particle dispersant (c) is absorbed on the surface of the oil phase (a); and the silica particle dispersant (c) is partially wetted by the polar phase (b).

Abstract: Novel metabolites of talarazole of formula (I) have been isolated and characterized, wherein R?H, OH, OSO3H or O-gly; R1, ?H, OH, OSO3H, O-gly or =0; and gly=a glucuronate, or a pharmaceutically acceptable salt thereof. These compounds are targeted for the treatment of various skin-, hair- and nail-associated disorders.

Abstract: Novel metabolites of talarazole of formula (I) have been isolated and characterized, wherein R?H, OH, OSO3H or O-gly; R1, ?H, OH, OSO3H, O-gly or =0; and gly=a glucuronate, or a pharmaceutically acceptable salt thereof. These compounds are targeted for the treatment of various skin-, hair- and nail-associated disorders.

Abstract: A method of making an oral dosage form of a water insoluble drug such as Saquinavir or Cyclosporine or Paclitaxel is carried out by: (a) providing a single phase working Solution comprising or consisting essentially of an active agent, water, a water-soluble polymer, and a solvent, said solvent selected from the group consisting of alcohol, acetone, and mixtures thereof; and may or may not contain a surfactant and pH of the said working solution may or may not be adjusted (b) providing particles formed from a pharmaceutically acceptable core material; (c) combining, preferably by spraying, said working solution with said particles to produce active agent-coated particles; such drug loaded particles may contain an external coat (d) drying said active agent-coated particles; and (e) forming said dried particles into an oral dosage form. Dried particles produced by the process, oral dosage forms containing such particles, and methods of treatment therewith are also described.

Abstract: Topical anti-pruritic compositions and methods of using the same to treat pruritus. These anti-pruritic compositions are capable of temporarily or permanently reducing, inhibiting, treating, ameliorating, and/or preventing pruritic skin conditions, as well as other related skin conditions. In a particular aspect, the present formulations provide a quicker and more effective treatment of pruritus than do certain present pruritus-treating compositions.

Abstract: A container venting disc is punctuated with gaps around the periphery to allow gases from the interior of the container to vent. An intermediate ridge or layer that abuts or is proximal to the interior edge of the container lip is implemented to prevent the disc from significantly moving laterally and to also center the venting disc within the container mouth. The gap(s) forms a channel in the disc to allow gases to escape between the edge of the container mouth and the container cap. The simplicity of design allows for easy manufacture and simple placement in a container, such as for a jar or bottle.

Abstract: Novel crystalline forms of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one, pharmaceutical compositions containing these crystalline forms, methods of using these crystalline forms for treating and/or preventing various microbial and/or fungal infections or disorders, and processes for obtaining these crystalline forms. In particular, the present subject matter relates to the specific crystalline Forms I, II, III, IV, V, and VI of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one.

Abstract: Novel crystalline forms of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2 -hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one, pharmaceutical compositions containing these crystalline forms, methods of using these crystalline forms for treating and/or preventing various microbial and/or fungal infections or disorders, and processes for obtaining these crystalline forms.

Abstract: Novel metabolites of talarazole of formula (I) have been isolated and characterized, wherein R?H, OH, OSO3H or O-gly; R1, ?H, OH, OSO3H, O-gly or =0; and gly=a glucuronate, or a pharmaceutically acceptable salt thereof. These compounds are targeted for the treatment of various skin-, hair- and nail-associated disorders.

Abstract: Novel compositions of matter comprising a foamable delivery system are provided. Novel methods for treating a disease, disorder, or condition using the novel compositions are further provided. Novel methods for making and delivering a foamable pharmaceutical composition are also provided. While the novel compositions and foamable drug delivery system may be utilized for administration of a wide variety of drugs to epithelial tissues, to treat a wide variety of diseases, disorders, or conditions, the inventive compositions and foamable drug delivery systems are particularly useful for the dermatological administration of corticosteroids and antifungal agents.

Abstract: Topical compositions and methods of using same for treating skin disorders or conditions comprising a storage-stable mixture of a benzoyl peroxide dispersion, clindamycin or pharmaceutically acceptable salts or esters thereof, and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a crosslinked hyaluronic acid that can be obtained according to a process comprising: (a) activation of a hyaluronic acid, (b) reaction of the activated hyaluronic acid with an oligopeptide- or polypeptide-based crosslinking agent, in a reaction medium adjusted to a pH of from 8 to 12, so as to obtain a crosslinked hyaluronic acid, (c) adjustment of the pH of the reaction medium to a value ranging from 5 to 7, and (d) precipitation of the crosslinked hyaluronic acid from an organic solvent. It also relates to the above process, to a hydrogel obtained from the crosslinked hyaluronic acid and to the use of the crosslinked hyaluronic acid for the manufacture of implants that can be used in particular in plastic surgery.

Abstract: A method for treating rosacea in a patient comprising administering to a patient suffering from rosacea a first topical composition comprising at least one sulfacetamide or a derivative thereof and at least one sunscreen, wherein the administration of said first composition provides a more effective treatment of said rosacea in comparison to treatment of rosacea achieved by administration of a second topical composition comprising metronidazole.

Abstract: Pharmaceutical delivery systems suitable for topical administration including benzoyl peroxide. In a particular aspect, these pharmaceutical delivery systems comprise at least one pad and a drug composition comprising benzoyl peroxide absorbed onto the pad. These compositions are used for topical medical applications, particularly to treat various skin disorders.